Swiss pharmaceutical giant Novartis has raised its annual profit forecast for the third quarter in a row, driven by the strong sales of its key treatments for psoriasis and cancer. The company now anticipates a high double-digit growth in core operating profit for the year, with sales expected to see low double-digit growth.
Previously, Novartis had projected core operating profit to grow in the mid to high double-digit range and sales to increase from high single digits to low double digits.
